F. Massari

发表

Postmenopausal women with sarcopenia have higher prevalence of falls and vertebral fractures.

L. R. Brun, M. Zanchetta, V. Longobardi, 2021, Medicina.

J. Zanchetta, C. Bogado, M. Zanchetta, 2011, Current osteoporosis reports.

Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study

C. Bogado, M. Zanchetta, J. Zanchetta, 2017, Osteoporosis International.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Jacques P. Brown, H. Genant, A. Grauer, 2017, The Lancet.

Denosumab: an update.

Zanchetta, J. Zanchetta, C. Bogado, 2011, Drugs of today.

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

A. Grauer, R. Dinavahi, C. Libanati, 2019, Osteoporosis International.

Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.

A. Insúa, J. R. Rodríguez Moncalvo, F. Massari, 2002, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Romosozumab Improves Lumbar Spine Bone Mass and Bone Strength Parameters Relative to Alendronate in Postmenopausal Women: Results From the ARCH Trial.

Jacques P. Brown, T. Keaveny, K. Engelke, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Parathyroid Hormone (1–84) and Teriparatide in the Treatment of Postmenopausal Osteoporosis

J. Zanchetta, C. Bogado, F. Massari, 2006, Women's health.

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

Jacques P. Brown, T. Keaveny, K. Engelke, 2021, Journal of Bone and Mineral Research.

OP0100 Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study

A. Grauer, T. Keaveny, K. Engelke, 2016 .

Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study

Jacques P. Brown, H. Genant, T. Keaveny, 2016 .

Argentine Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Postmenopausal Women and Men Aged 50 Years and Older

G. Berbotto, M. L. Brance, M. Zanchetta, 2023, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Assessment of Motor Performances in Italian Primary School Children: Results of SBAM Project

D. Colella, Domenico Monacis, F. Massari, 2019, Advances in Physical Education.

Impaired Bone Microarchitecture Improves After One Year On Gluten‐Free Diet: A Prospective Longitudinal HRpQCT Study in Women With Celiac Disease

J. Zanchetta, E. Smecuol, M. Moreno, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.